FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like SoCal's Evolus Files for $75M IPO January 8, 2018 MacroGenics Announces Date Of Fourth Quarter And Full Year 2016 Financial Results Conference Call February 16, 2017 Stanford University Clinical Geneticist Begins Presidency With The March 22, 2017
MacroGenics Announces Date Of Fourth Quarter And Full Year 2016 Financial Results Conference Call February 16, 2017
